ID   Ma-Mel-48a
AC   CVCL_A183
SY   Ma-Mel_48A; Ma-Mel-48A; Ma-Mel 48a
DR   cancercelllines; CVCL_A183
DR   Cosmic; 1846629
DR   Cosmic; 2163863
DR   Cosmic; 2686417
DR   Cosmic; 2757113
DR   ESTDAB; ESTDAB-195
DR   GEO; GSM109068
DR   GEO; GSM1467846
DR   Progenetix; CVCL_A183
DR   Wikidata; Q54903805
RX   PubMed=16827748;
RX   PubMed=17311103;
RX   PubMed=19340423;
RX   PubMed=23348503;
RX   PubMed=23851445;
RX   PubMed=25294904;
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Gly469Arg (c.1405G>A); ClinVar=VCV000177775; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503; PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503).
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Skin; UBERON=UBERON_0002097.
ST   Source(s): ESTDAB=ESTDAB-195
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 14
ST   D3S1358: 18
ST   D5S818: 11,12
ST   D7S820: 9
ST   FGA: 21,23
ST   TH01: 6,8
ST   TPOX: 8,10
ST   vWA: 17,19
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_N786 ! Ma-Mel-48b
OI   CVCL_N787 ! Ma-Mel-48c
SX   Male
AG   87Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 19-12-24; Version: 22
//
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R.,
RA   Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D.,
RA   Dummer R.;
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
//
RX   PubMed=17311103; DOI=10.1371/journal.pone.0000236; PMCID=PMC1794595;
RA   Ugurel S., Thirumaran R.K., Bloethner S., Gast A., Sucker A.,
RA   Mueller-Berghaus J., Rittgen W., Hemminki K., Becker J.C., Kumar R.,
RA   Schadendorf D.;
RT   "B-RAF and N-RAS mutations are preserved during short time in vitro
RT   propagation and differentially impact prognosis.";
RL   PLoS ONE 2:E236-E236(2007).
//
RX   PubMed=19340423; DOI=10.1007/s00262-009-0701-z; PMCID=PMC11030131;
RA   Mendez R., Aptsiauri N., Del Campo A., Maleno I., Cabrera T.,
RA   Ruiz-Cabello Osuna F., Garrido F., Garcia-Lora A.;
RT   "HLA and melanoma: multiple alterations in HLA class I and II
RT   expression in human melanoma cell lines from ESTDAB cell bank.";
RL   Cancer Immunol. Immunother. 58:1507-1515(2009).
//
RX   PubMed=23348503; DOI=10.1126/science.1230062;
RA   Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A.,
RA   Kadel S., Moll I., Nagore E., Hemminki K., Schadendorf D., Kumar R.;
RT   "TERT promoter mutations in familial and sporadic melanoma.";
RL   Science 339:959-961(2013).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//
RX   PubMed=25294904; DOI=10.1158/1078-0432.CCR-14-0567; PMCID=PMC8728890;
RA   Sucker A., Zhao F., Real B., Heeke C., Bielefeld N., Massen S.,
RA   Horn S., Moll I., Maltaner R., Horn P.A., Schilling B., Sabbatino F.,
RA   Lennerz V., Kloor M., Ferrone S., Schadendorf D., Falk C.S.,
RA   Griewank K.G., Paschen A.;
RT   "Genetic evolution of T-cell resistance in the course of melanoma
RT   progression.";
RL   Clin. Cancer Res. 20:6593-6604(2014).
//